Generate Biomedicines (NASDAQ:GENB) Rating Lowered to Sell at Wall Street Zen

Generate Biomedicines (NASDAQ:GENB - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

GENB has been the subject of a number of other reports. HC Wainwright increased their price target on Generate Biomedicines from $16.00 to $25.00 and gave the stock a "buy" rating in a report on Friday. The Goldman Sachs Group started coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a "buy" rating and a $26.00 price objective on the stock. Zacks Research raised shares of Generate Biomedicines to a "hold" rating in a research report on Wednesday, March 25th. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an "overweight" rating for the company. Finally, Morgan Stanley started coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They issued an "overweight" rating and a $20.00 price target on the stock. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, Generate Biomedicines currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.

Generate Biomedicines Stock Performance

GENB opened at $13.66 on Friday. Generate Biomedicines has a one year low of $11.00 and a one year high of $15.89. The firm has a 50 day simple moving average of $12.62.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.